antibody

GOAT ANTI HUMAN GFAP (C-TERMINAL)

MBS222916

0.1 mg

500 USD

polyclonal

goat

nonconjugated

human, mouse, rat, dog

western blot, ELISA, enzyme immunoassay

Antibody

GOAT ANTI HUMAN GFAP (C-TERMINAL)

GFAP

glial fibrillary acidic protein isoform 2; Glial fibrillary acidic protein; glial fibrillary acidic protein; glial fibrillary acidic protein

GFAP

GFAP; GFAP; GFAP

GFAP_HUMAN

Polyclonal

IgG

Goat

Dog (Expected from Sequence), Mouse, Rat (Expected from Sequence)

431

This item recognises an epitope within the C-terminal (CT) region of human GFAP (glial fibrillary acidic protein), a class III intermediate filament (IF) protein specifically expressed by glial cells or cells of glial origin e.g astrocytes, ependymal cells and Schwann cells. GFAP plays a role in several cellular functions within the central nervous system (CNS), including cell structure and stability, communication, motility and mitosis, and is rapidly synthesized during astrogliosis, following trauma/injury. Mutations in the GFAP gene are responsible for the rare autosomal dominant disorder known as Alexander disease, resulting in the destruction of brain white matter and the formation of fibrous, eosinophilic deposits known as Rosenthal fibers. Characteristics of this disease are associated with transgenes and other mutation types in mouse.

Purified. Purified IgG - liquid

IgG concentration 0.5mg/ml

Store at 4 degree C or at -20 degree C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. Shelf Life: 18 months from date of despatch.

ELISA (EIA), Western Blot (WB)

Western Blot: This item detects a band of approximately 48kDa in mouse brain cell lysates. ELISA: Maximum Dilution: 1/32000. Western Blotting: Minimum Dilution: 1.0; Maximum Dilution: 3.0ug/ml

Perservative Stabilisers: 0.02% Sodium Azide (NaN3). 0.5% Bovine Serum Albumin

Immunogen: Peptide sequence C-DGEVIKESKQEHKD from the C-terminal region of GFAP (NP_002046.1). Buffer Solution: TRIS buffered saline. Antiserum Preparation: Antiserum to human GFAP (CT) was raised by repeated immunisation of goats with highly purified antigen. Purified IgG was prepared from whole serum by affinity chromatography. Target Species: Human

MBS222916 recognises an epitope within the C-terminal (CT) region of human GFAP (glial fibrillary acidic protein), a class III intermediate filament (IF) protein specifically expressed by glial cells or cells of glial origin e.g astrocytes, ependymal cells and Schwann cells. GFAP plays a role in several cellular functions within the central nervous system (CNS), including cell structure and stability, communication, motility and mitosis, and is rapidly synthesized during astrogliosis, following trauma/injury. Mutations in the GFAP gene are responsible for the rare autosomal dominant disorder known as Alexander disease, resulting in the destruction of brain white matter and the formation of fibrous, eosinophilic deposits known as Rosenthal fibers. Characteristics of this disease are associated with transgenes and other mutation types in mouse.

196115290

NP_001124491.1

NM_001131019.2

P14136

49,508 Da

Neural Crest Differentiation Pathway 672460!!Nuclear Signaling By ERBB4 Pathway 530744!!Signal Transduction Pathway 477114!!Signaling By ERBB4 Pathway 530741!!Spinal Cord Injury Pathway 739007

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]

0.1 mg

500 USD